- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05753878
A Study to Evaluate the Safety and Pharmacokinetics of HH-120 Nasal Spray in Healthy Volunteers
September 25, 2023 updated by: Huahui Health
A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic and Immunogenicity of HH-120 Nasal Spray in Healthy Subjects
This is a clinical study evaluating the safety, tolerability, pharmacokinetic (PK) characteristics and immunogenicity of HH-120 nasal spray in healthy subjects.
This study is divided into two parts: Part A is of open-label design and mainly aims to assess the local distribution and PK in nasal cavity of HH-120 nasal spray, subjects from 10 cohorts are sequentially enrolled to perform either nasal endoscopic examination or nasal/ nasopharyngeal samples collection at different time points post administration.
Part B mainly aims to assess the safety, systematic pharmacokinetic and immunogenicity after multiple dosing of HH-120 nasal spray, subjects are randomly assigned (3:1) to HH-120 and placebo groups.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
62
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100730
- Beijing Tongren Hospital, Capital Medical University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Male and female subjects aged 18 to 65 (including 18 and 65 years old);
- The weight of male subjects is not less than 50 kg, and the weight of female subjects is not less than 45 kg. Body Mass Index (BMI) = weight (kg)/height2 (m2), BMI is within the range of 18~28kg/m2 (including the critical value);
- Normal physical examination, vital signs, laboratory tests and other auxiliary examinations (chest imaging, abdominal B-ultrasound, electrocardiogram, etc.) or abnormality without clinical significance.
- Willing and able to give written informed consent.
Exclusion Criteria:
- Participated in any other clinical research with drug intervention within 4 weeks before screening, or the drug is still in the elimination period (5 half-lives) before screening, whichever is longer;
- Have used therapeutic biological agents within 12 weeks before screening, or are within the drug elimination period (5 half-lives) at the time of random administration, whichever is longer;
- Have been vaccinated within 12 weeks before screening, or plan to receive BCG or other vaccines during the study or within 12 weeks after the study;
- Have used any prescription drugs, non-prescription Chinese herbal medicines or health products within 14 days (inclusive) before the screening;
- Have undergone any major surgery within 8 weeks (including 8 weeks) before screening, or need to undergo such surgery during the study period, and deemed by the investigator and the sponsor that such surgery may bring unacceptable risk to the subject.;Physical examination, laboratory abnormalities, and medical history;
- Supine systolic blood pressure (SBP) >140mmHg or <90 mmHg, and/or diastolic blood pressure (DBP) >90mmHg or <50 mmHg during the screening period;
- Supine 12-lead electrocardiogram showing QTcF interval > 450 ms (male) or > 470 ms (female). and/or other abnormalities with clinical significance during screening;
- History of systemic or respiratory infection within 2 weeks before screening, or concurrent viral or bacterial infection (fever or other symptoms) during screening;
- Have received vital organ transplantation (such as heart, lung, liver, kidney, etc.);
- Have malignant tumor diseases (excluding malignant tumors that have been cured and have no recurrence within the past 5 years, completely resected basal cell and squamous cell skin cancers, and completely resected carcinoma in situ of any type);
- Hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (Anti-HCV), Treponema pallidum antibody and acquired immunodeficiency syndrome (HIV) antibody positive;
- History of cardiovascular system, digestive system, kidney, liver, endocrine system, blood and lymphatic system, immune, nervous system or mental disorders or any other significant diseases, or suffer from chronic rhinitis or allergic rhinitis, drug abuse, alcoholism
- Have a history of drug abuse or used drugs in the past six months or have a positive urine drug screening;
- Have a history of alcoholism or excessive alcohol intake in the past 6 months (drinking 14 units of alcohol per week: 1 unit = 285mL of beer, or 25mL of spirits, or 100mL of wine), or those who have a positive alcohol breath test; or test Cannot cooperate with non-drinkers during the period;
- Known hypersensitivity to any ingredient used in the dosage form of intervention therapy; ever hypersensitivity (regardless of degree) to other monoclonal antibody drugs and therapeutic protein preparations (fresh or frozen plasma, human serum albumin, cytokines, interleukins, etc.) ; or have a clear past allergy to inhalant allergens (regardless of degree);
- History of severe allergic reactions or hypersensitivity reactions, or those with allergic constitution (allergic to multiple drugs and food);
- Have child-bearing plan or are unable to voluntarily take effective contraceptive measures, or plan to donate sperm/ovum;
- Positive for human chorionic gonadotropin (β-Human Chorionic Gonadotropin, β-HCG) or are breastfeeding;
- Have blood losing >400mL in the past 3 months, or have received blood transfusion; or plan to donate blood during the study;
- Any other circumstances that the researchers deemed not suitable for participating in the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HH-120 nasal spray, Part A cohort 1
Nasal endoscopic examination is performed at 3min (±2 min), 30min (±5 min), 1h (±10 min), and 2h (±10 min) after dosing.
|
A single dose of HH-120 nasal spray premixed with 1mg/ml methylene blue injection.
|
Experimental: HH-120 nasal spray, Part A cohort 2-7
Nasal/nasopharyngeal samples are collected at 3min (±2 min) , 1h (±10 min) ,2h (±10 min),4h (±30 min),8h (±30 min),24h (±30 min).
|
A single dose of HH-120 nasal spray.
|
Experimental: HH-120 nasal spray, Part A cohort 8-9
Nasal/nasopharyngeal samples are collected at 4h (±30 min) , 8h (±30 min).
|
Two doses of HH-120 nasal spray.
|
Experimental: HH-120 nasal spray, Part B
|
HH-120 nasal spray, 10 times daily for 7 consecutive days.
|
Placebo Comparator: Placebo nasal spray, Part B
|
Placebo nasal spray, 10 times daily for 7 consecutive days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The distribution of HH-120 in the nasal cavity at different time points after single dose of HH-120 nasal spray.(Part A: cohort 1)
Time Frame: From baseline to the end of the 7-day follow-up.
|
From baseline to the end of the 7-day follow-up.
|
Local drug concentration of nasal and nasopharyngeal swab samples before and at different time points after dosing of HH-120 nasal spray.(Part A: cohort 2-9)
Time Frame: From baseline to the end of the 7-day follow-up.
|
From baseline to the end of the 7-day follow-up.
|
The incidence and severity of adverse events and the serious adverse events.(Part B)
Time Frame: From baseline to the end of the 29-day follow-up.
|
From baseline to the end of the 29-day follow-up.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The incidence and severity of adverse events and the serious adverse events.(Part A)
Time Frame: From baseline to the end of the 7-day follow-up.
|
From baseline to the end of the 7-day follow-up.
|
Drug concentration of nasopharyngeal swab samples before and after multiple dosing of HH-120 nasal spray.(Part B)
Time Frame: From baseline to the end of the 29-day follow-up.
|
From baseline to the end of the 29-day follow-up.
|
Maximum plasma concentration (Cmax).(Part B)
Time Frame: From baseline to the end of the 29-day follow-up.
|
From baseline to the end of the 29-day follow-up.
|
Peak time (Tmax).(Part B)
Time Frame: From baseline to the end of the 29-day follow-up.
|
From baseline to the end of the 29-day follow-up.
|
The incidence and titer of anti-drug antibody (ADA).(Part B)
Time Frame: From baseline to the end of the 29-day follow-up.
|
From baseline to the end of the 29-day follow-up.
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The in vitro SARS-CoV-2 neutralization activity of nasal and nasopharyngeal swab samples at different time points after dosing.(Part A)
Time Frame: From baseline to the end of the 7 days follow-up.
|
From baseline to the end of the 7 days follow-up.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 8, 2022
Primary Completion (Actual)
January 9, 2023
Study Completion (Actual)
January 9, 2023
Study Registration Dates
First Submitted
February 23, 2023
First Submitted That Met QC Criteria
February 23, 2023
First Posted (Actual)
March 3, 2023
Study Record Updates
Last Update Posted (Actual)
September 28, 2023
Last Update Submitted That Met QC Criteria
September 25, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- HH120-NS111
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on HH-120 nasal spray, PartA cohort 1
-
Beijing Ditan HospitalCompleted
-
Beijing Ditan HospitalCompletedCoronavirus Disease 2019(COVID-19)China
-
Beijing Ditan HospitalCompletedCOVID-19 | SARS-CoV-2 InfectionChina
-
Huahui HealthRecruiting
-
Huahui HealthRecruiting
-
Huahui HealthCompletedCOVID-19 Respiratory InfectionAustralia
-
Food and Drug Administration (FDA)Spaulding Clinical Research LLCCompletedClinical Study to Investigate the Pharmacokinetics of Multiple Repeated Doses of Intranasal NaloxoneHealthy Subjects | Pharmacokinetics | Opioid AntagonistUnited States
-
Pharmacyclics LLC.TerminatedAcute Myeloid Leukemia (AML)United States
-
NorthShore University HealthSystemRecruitingChronic RhinitisUnited States
-
Beijing Tongren HospitalUnknownObstructive Sleep ApneaChina